The Impact of Tamoxifen and Aromatase Inhibitors on Platelet Proteins
This trial is active, not recruiting.
|Sponsor||University of Vermont|
|Collaborator||American Cancer Society, Inc.|
|Start date||August 2009|
|End date||October 2010|
|Trial size||60 participants|
|Trial identifier||NCT01341171, V0805|
Single phlebotomy study involving women receiving tamoxifen or aromatase inhibitor therapy.
Angiogenic Protein levels
time frame: following 6 months of therapy
Female participants at least 18 years old.
Inclusion Criteria: - women routinely taking tamoxifen or aromatase inhibitor therapy as prescribed by their oncologist Exclusion Criteria: - Use of heparin, warfarin
|Official title||Platelet Modulation in the Control of Angiogenesis: The Impact of Tamoxifen and Aromatase Inhibitors on Platelet Activation and Angiogenic Proteins|
|Principal investigator||Chris E Holmes, MD, PhD|
Call for more information